NEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Diebold Nixdorf (NYSE: DBD) topped third-quarter revenue estimates on October 28, 2026, and its shares still fell as investors reacted to a full-year adjusted EBITDA outlook cut by $20-$25 million. If you bought DBD and your position is now underwater, this investigation concerns your losses. Shareholders who lost money are encouraged to submit their DBD loss details now, or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Third-quarter revenue came in above analyst consensus. Adjusted EBITDA grew. Investors sold anyway, reacting to what management said about the rest of 2026 rather than to the quarter just reported.

In the same October 28 release, Diebold Nixdorf lowered its full-year adjusted EBITDA guidance to a range of $490 million to $510 million, down from $510 million to $535 million. That is a $22.5 million cut at the midpoint, or roughly 4.3%. Revenue, adjusted EPS, and free cash flow targets were reduced alongside it. Levi & Korsinsky is investigating potential securities law violations on behalf of DBD investors who suffered losses following the outlook reduction.

Investors who lost money on DBD after the October 28 outlook cut can request a free review of their losses or call (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the DBD Investigation

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Diebold Nixdorf made materially false or misleading statements regarding its full-year 2026 outlook, including any subsequent reaffirmations or reiterations thereof. When the Company ultimately disclosed significant reductions to its guidance, the stock price declined.

Q: Who is eligible to participate in the DBD investigation? A: Investors who purchased DBD stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do DBD investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my DBD shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought DBD and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP